Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Daphne M. Hullegie-Peelen"'
Autor:
Lukas K. van Vugt, Marieke van der Zwan, Marian C. Clahsen-van Groningen, Madelon van Agteren, Daphne M. Hullegie-Peelen, Brenda C. M. De Winter, Marlies E. J. Reinders, Pedro Miranda Afonso, Dennis A. Hesselink
Publikováno v:
Transplant International, Vol 36 (2023)
Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejectio
Externí odkaz:
https://doaj.org/article/cfd685a2a41d4895a6c64720351229a2
Autor:
Daphne M. Hullegie-Peelen, Hector Tejeda Mora, Dennis A. Hesselink, Eric M.J. Bindels, Thierry P.P. van den Bosch, Marian C. Clahsen-van Groningen, Marjolein Dieterich, Sebastiaan Heidt, Robert C. Minnee, Georges M.G.M. Verjans, Martin J. Hoogduijn, Carla C. Baan
Publikováno v:
JCI Insight, Vol 8, Iss 21 (2023)
Tissue-resident lymphocytes (TRLs) are critical for local protection against viral pathogens in peripheral tissue. However, it is unclear if TRLs perform a similar role in transplanted organs under chronic immunosuppressed conditions. In this study,
Externí odkaz:
https://doaj.org/article/fb29d72fe9e1487c9936e377474c2faa
Publikováno v:
Pharmacogenomics, 23(10), 567-570. Future Medicine Ltd.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::702298d1367fbd5f14d6b90f606edfb5
https://doi.org/10.2217/pgs-2022-0071
https://doi.org/10.2217/pgs-2022-0071